Aeromics

About:

Aeromics is a clinical candidate targeting a molecular water channel for the treatment of cerebral edema in stroke.

Website: http://aeromics.com

Top Investors: Connecticut Innovations, Broadview Ventures

Description:

Aeromics is a clinical candidate targeting a molecular water channel for the treatment of cerebral edema in stroke. A paradigm shift in its understanding of water physiology was the discovery aquaporins, proteins that form water channels to allow water into and out of cells, by Peter Agre (2003 Nobel Prize in Chemistry). Despite the vital role of aquaporins in maintaining water homeostasis and its implications in various disease states, therapeutic agents targeting aquaporins have until now remained elusive. Aeromics’ drug candidate, AER-271, targets aquaporin-4 (AQP4), the primary water channel in the brain, and has best-in-class credentials for acute intravenous therapy for stroke-related cerebral edema (CE).

Total Funding Amount:

$12.6M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cleveland, Ohio, United States

Founded Date:

2006-01-01

Contact Email:

info(AT)aeromics.com

Founders:

Marc F. Pelletier, Walter F. Boron

Number of Employees:

1-10

Last Funding Date:

2017-10-19

IPO Status:

Private

Industries:

© 2025 bioDAO.ai